![Teva Announces Sale of Remaining Assets in Specialty Global Women's Health Portfolio for $1.38 Billion – Sawaya Partners., LLC Teva Announces Sale of Remaining Assets in Specialty Global Women's Health Portfolio for $1.38 Billion – Sawaya Partners., LLC](https://www.sawayapartners.com/wp-content/uploads/2017/11/Teva-1170x560.jpg)
Teva Announces Sale of Remaining Assets in Specialty Global Women's Health Portfolio for $1.38 Billion – Sawaya Partners., LLC
![SEASONIQUE Market Exclusivity Period (MEP). When do the SEASONIQUE patents expire, and when will SEASONIQUE go generic? SEASONIQUE Market Exclusivity Period (MEP). When do the SEASONIQUE patents expire, and when will SEASONIQUE go generic?](https://www.drugpatentwatch.com/p/graph/s/t/SEASONIQUE-patent-expirations.png)
SEASONIQUE Market Exclusivity Period (MEP). When do the SEASONIQUE patents expire, and when will SEASONIQUE go generic?
![Norethindrone acetate versus extended-cycle oral contraceptive (Seasonique®) in the treatment of endometriosis symptoms: A prospective open-label comparative study - European Journal of Obstetrics and Gynecology and Reproductive Biology Norethindrone acetate versus extended-cycle oral contraceptive (Seasonique®) in the treatment of endometriosis symptoms: A prospective open-label comparative study - European Journal of Obstetrics and Gynecology and Reproductive Biology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/2119013517/2088001098/gr1.jpg)
Norethindrone acetate versus extended-cycle oral contraceptive (Seasonique®) in the treatment of endometriosis symptoms: A prospective open-label comparative study - European Journal of Obstetrics and Gynecology and Reproductive Biology
![Teva completes $703M sale of women's health products to CVC Capital Partners. - Philadelphia Business Journal Teva completes $703M sale of women's health products to CVC Capital Partners. - Philadelphia Business Journal](https://media.bizj.us/view/img/10777492/47002105ovaleap300ie-0-5ml*750xx640-360-0-60.jpg)
Teva completes $703M sale of women's health products to CVC Capital Partners. - Philadelphia Business Journal
![Seasonique (Teva) el primer anticonceptivo oral que reduce el número de reglas anuales a cuatro – Blog Policlínico Valencia Seasonique (Teva) el primer anticonceptivo oral que reduce el número de reglas anuales a cuatro – Blog Policlínico Valencia](https://policlinicovalencia.es/blog/wp-content/uploads/2016/10/seasonique.png)